Endpoints 11
September 19, 2025

Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups

WALTHAM, Mass., Sept. 19, 2025 – Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative...

Read More
July 10, 2025

Comments from Dr. Shefali Agarwal, President and CEO, on Agreement with Novartis

...

Read More
July 9, 2025

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

WALTHAM, Mass, July 9, 2025 – Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational...

Read More
June 30, 2025

Sironax Accelerates Global Expansion

Following significant progress in its R&D pipeline, Sironax is embarking on a new phase of global expansion, focusing on the clinical development...

Read More
May 8, 2025

Sironax Story | Build the Bridge From Bench to Bedside for Degenerative Diseases

Developing innovative therapies for degenerative diseases presents scientific and clinical challenges at every stage – from early discovery to...

Read More
April 22, 2025

Sironax Completed Phase I study for SIR2501

Sironax has recently completed its Phase I clinical trial for SIR2501, an innovative drug candidate with potential to treat neurodegenerative and...

Read More
March 31, 2025

Sironax Celebrates US Team Expansion And China IND Approvals

Today marked a milestone moment for Sironax. We celebrated recent transformative achievements – the strategic expansion of our US team and IND...

Read More
August 2, 2022

Sironax Announces Closing of $200 Million Series B Financing

Beijing, August 2, 2022 – Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for...

Read More